Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Fish and Richardson
Medtronic
Federal Trade Commission
Cantor Fitzgerald
Cipla
Colorcon
Chinese Patent Office
Boehringer Ingelheim

Generated: June 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,432,440

« Back to Dashboard

Which drugs does patent 6,432,440 protect, and when does it expire?

Patent 6,432,440 protects LAZANDA and is included in one NDA.

This patent has twenty-one patent family members in fourteen countries.
Summary for Patent: 6,432,440
Title: Pectin compositions and methods of use for improved delivery of drugs to mucosal surfaces
Abstract:Liquid pharmaceutical compositions for administration to a mucosal surface, comprising a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions.
Inventor(s): Watts; Peter James (Nottingham, GB), Illum; Lisbeth (Nottingham, GB)
Assignee: West Pharmaceutical Services Drug Delivery & Clinical Research Centre ( (Nottingham, GB)
Application Number:09/402,976
Patent Claim Types:
see list of patent claims
Composition; Delivery; Dosage form; Formulation; Device; Use; Process;

Drugs Protected by US Patent 6,432,440

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Elefsee Pharms Intl LAZANDA fentanyl citrate SPRAY, METERED;NASAL 022569-001 Jun 30, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN ➤ Sign Up
Elefsee Pharms Intl LAZANDA fentanyl citrate SPRAY, METERED;NASAL 022569-002 Jun 30, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,432,440

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9707934Apr 18, 1997
PCT Information
PCT FiledApril 20, 1998PCT Application Number:PCT/GB98/01147
PCT Publication Date:October 29, 1998PCT Publication Number: WO98/47535

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Accenture
Federal Trade Commission
Baxter
Express Scripts
Colorcon
Julphar
Farmers Insurance
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.